Literature DB >> 20454838

Novel cyclopeptides for the design of MMP directed delivery devices: a novel smart delivery paradigm.

El-Farouck Moustoifa1, Mohamed-Anis Alouini, Arnaud Salaün, Thomas Berthelot, Aghleb Bartegi, Sandra Albenque-Rubio, Gérard Déléris.   

Abstract

PURPOSE: Matrix metalloproteinases (MMP) are a family of proteolytic enzymes, the expression of which in a key step of tumor progression has been better defined recently. The studies highlighted the ongoing need for very specific inhibitors, substrates or release devices designed to be selective for one or at least very few MMPs.
METHODS: This report deals with the design, synthesis and in vitro evaluation of linear and especially novel cyclic peptidic moieties, embodying MMP cleavable sequences designed to answer these questions. FRET (fluorescence resonance energy transfer) labelling via chromophore-modified amino-acids was used to give access to enzyme kinetics.
RESULTS: Evaluation of these peptides showed that cyclisation gives rise to high specificity for certain MMP, suggesting that this approach could provide very specific MMP substrate. Moreover, cyclic structures present a very good plasma stability.
CONCLUSIONS: These original derivatives could allow the design of MMP-controlled delivery devices, the specificity of which will be retained in complex biological media and in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20454838     DOI: 10.1007/s11095-010-0164-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  34 in total

Review 1.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

Review 2.  Matrix metalloproteinases: they're not just for matrix anymore!

Authors:  L J McCawley; L M Matrisian
Journal:  Curr Opin Cell Biol       Date:  2001-10       Impact factor: 8.382

Review 3.  Matrix metalloproteinases as modulators of inflammation and innate immunity.

Authors:  William C Parks; Carole L Wilson; Yolanda S López-Boado
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

Review 4.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

Authors:  Christopher M Overall; Oded Kleifeld
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

Review 5.  Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides.

Authors:  H Nagase; G B Fields
Journal:  Biopolymers       Date:  1996       Impact factor: 2.505

6.  Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats.

Authors:  Toshiaki Aoki; Toshihisa Sumii; Tatsuro Mori; Xiaoying Wang; Eng H Lo
Journal:  Stroke       Date:  2002-11       Impact factor: 7.914

7.  A model for interstitial collagen catabolism by mammalian collagenases.

Authors:  G B Fields
Journal:  J Theor Biol       Date:  1991-12-21       Impact factor: 2.691

8.  Matrix metalloprotease triggered delivery of cancer chemotherapeutics from hydrogel matrixes.

Authors:  Jovita R Tauro; Richard A Gemeinhart
Journal:  Bioconjug Chem       Date:  2005 Sep-Oct       Impact factor: 4.774

9.  Synthesis of N epsilon-(7-diethylaminocoumarin-3-carboxyl)- and N epsilon-(7-methoxycoumarin-3-carboxyl)-L-Fmoc lysine as tools for protease cleavage detection by fluorescence.

Authors:  Thomas Berthelot; Jean-Claude Talbot; Georges Laïn; Gérard Déleris; Laurent Latxague
Journal:  J Pept Sci       Date:  2005-03       Impact factor: 1.905

10.  Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9.

Authors:  J Ochieng; R Fridman; P Nangia-Makker; D E Kleiner; L A Liotta; W G Stetler-Stevenson; A Raz
Journal:  Biochemistry       Date:  1994-11-29       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.